TaiGen Biotech Granted Taiwanese Approval for Novel Antibiotic

TaiGen Biotechnology received marketing approval in Taiwan for Taigexyn® (nemonoxacin), a new chemical entity that is aimed at community-acquired bacterial pneumonia. The approval is the first for TaiGen and for Taigexyn. In April 2013, TaiGen filed a new drug application for China approval of Taigexyn, which remains under review. TaiGen out-licensed China rights for Taigexyn to Zhejiang Medicine Co. in 2012, which made an $8 million upfront payment. More details.... Share this with colleagues: // //